All In Biotech

Drug Trial Radar · NCT04604509

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

PISCES I: Precision Implemented Smoking Cessation Evaluation Study

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,010 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,010

Planned (sponsor's estimate)

Start

Aug 4, 2020

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Oct 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.

Conditions

  • Cigarette Smoking-Related Carcinoma

Interventions

  • Bupropion Hydrochloride Controlled-releaseDrug

    Given PO

  • Nicotine ReplacementDrug

    Given via nicotine patch, lozenges, or gum

  • Questionnaire AdministrationOther

    Ancillary studies

  • Tobacco Cessation CounselingOther

    Receive behavioral smoking cessation counseling

  • VareniclineDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. End of treatment seven-day point prevalenceTime frame: Up to 6 months
  2. Expired carbon monoxide valueTime frame: Up to 6 months
  3. AbstinenceTime frame: At 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M D Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.